[The effectiveness of botulinum therapy of trigeminal neuralgia]. / Effektivnost' botulinoterapii pri trigeminal'noi nevralgii.

OBJECTIVE: To evaluate the treatment protocol with the use of onabotulinum toxin type A (botox) and the efficacy of a single botulinum therapy procedure for clinical manifestations in patients with trigeminal neuralgia (TN). MATERIAL AND METHODS: We studied 90 patients (57 women, 33 men), including 80 people with primary TN and 10 people with secondary TN. Then 20 patients with primary TN (11 women and 9 men, mean age 61.8 years) received local injections of onabotulinum toxin type A (botox). Clinical examination included taking anamnesis, assessment of pain on a visual analogue scale (VAS), assessment of the frequency of pain paroxysms, taking into account the average indicator (0 to 100 seizures during the day); neurosensory examination according to the developed protocol with the definition of pain, temperature, tactile sensitivity, the study of stimulus-dependent pain; MRI of the brain to diagnose neurovascular conflict. RESULTS: A month after the injections, the pain intensity practically did not change (8.5 versus 7.2 points on the VAS), but the number of paroxysms decreased (31.2 versus 22.5 seizures per day). Two months after the use of botox, the number of pain attacks continued to decrease (31.2 versus 17.7; Mann-Whitney U-test, p=0.006). At the same time, there was a decrease in pain intensity according to the VAS (8.5 versus 6.1, t-test 2.75 points; p=0.02). After three months, there was a decrease in the number of paroxysms from 31.2 to 9.2 (paired Student's test, p<0.001) and the severity of pain (8.85 versus 4.0 points on the VAS, paired t-test 3.95 points, p<0.001). There were significant differences in the average dose of carbamazepine (867.5 versus 670.8 after 3 months, t-test 196.7 mg, p=0.02). In TN patients who underwent destructive operations with exposure to the peripheral branches of the trigeminal nerve, signs of severe neurosensory deficit on the face and burning pain are added to the main symptoms, which corresponds to the clinical criteria of post-traumatic trigeminal neuropathy. CONCLUSION: Local injections of type A onabotulinum toxin (botox) are minimally invasive, safe and effective symptomatic therapy for patients with TN. Persistent sensory disturbances that develop in patients after destructive surgeries call into question the safety of these therapies for TN.

[Facial pain].

Diagnosis and treatment of facial pain is a problem for physicians of different specialties (neurologists, dentists, surgeons, oculists, otolaryngologists and psychiatrists). A classification of this pathology is far from ideal and an interdisciplinary comprehensive approach is needed. Current approaches to etiotropic, symptomatic and pathogenetic treatment of patients with most frequent variants of orofacial pain are presented.

[The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery].

AIM: To evaluate the role of botulinum toxin type A in the acute phase of facial nerve injury after neurosurgical surgery. MATERIALS AND METHODS: The study involved 55 patients with acute facial muscle paresis caused by facial nerve injury during surgery on the posterior cranial fossa and cerebello-pontine angle (CPA). The first group consisted of 35 patients (mean age, 48.14±1.26 years) who were administered botulinum toxin type A (xeomin) at a dose of 2-3 U per point in muscles of the intact side of the face. The control group included 20 patients (mean age, 49.85±1.4 years) who underwent standard rehabilitation treatment of this pathology. The treatment efficacy was evaluated using the House-Brackmann Scale, the Yanagihara facial grading system, the Facial Disability Index (FDI), and the Sunnybrook Facial Grading (SFG) Scale. RESULTS: Before treatment, patients of both groups experienced severe dysfunction according to the House-Brackmann Scale. A month after the botulinium toxin type A therapy had been started, a significant improvement in the group of patients who received botulinum toxin was observed at all scales (p<0.05), whereas improvement in the facial nerve function in the second group was observed only by the 3rd month of rehabilitation treatment (p<0.05). The number of synkineses in the patients who did not receive botulinum toxin was 46% higher than that in the first group (p=0.019) one year after the surgery, and it was higher by 91% after 2 years (p<0.001). CONCLUSIONS: The use of botulinum toxin type A is reasonable in acute facial nerve injury and should be mandatory in combined therapy of these patients.

[Risks for disease in preinduction age and the program of the recreation activity].

The study of the fitness for military service in the Republic of Bashkortostan according to the medical examination results has shown that the common morbidity in draft-age adolescents increased in four times. More significant risk factors determining the growth of chronic non-infectious diseases in adolescents were found to be low physical activities (79.3%), alcohol consumption (75.2%), smoking (52.8%), lack night sleeping (23.1%). A trend of increasing in risk factor prevalence and its age association were noted. The development sanitation programme of adolescents has shown the high efficiency in the formation of a healthy life.

[Efficiency of rehabilitation for oil-extracting industry workers suffering from arterial hypertension].

The article covers evaluation of integral health parameter on basis of studying functional body resources in arterial hypertension patients during sanatorium rehabilitation with iodine and bromine baths. The authors proved positive influence of the sanatorium management for arterial hypertension patients on regulatory systems parameters and on physical performance (according to veloergometry).

[Vascular decompression in the treatment of trigeminal neuralgia].

Trigeminal neuralgia is characterized by unilateral paroxysmal facial pain. Patients often describe this pain as "the most sever pain one can suffer". Vascular compression of trigeminal nerve root directly near brainstem by artery or vein is considered the main etiology of trigeminal neuralgia. Consequently, basic pathogenetic treatment is vascular decompression of trigeminal nerve root that allows to eliminate the cause of pain. 140 patients with trigeminal neuralgia were operated in Burdenko Neurosurgical Institute since 1998 to 2007. Pain relief after surgery was observed in 96% of cases. There was no mortality in our series, overall delayed complication rate was less than 1,5%. The article deals with clinical presentation of classic trigeminal neuralgia, evaluation of the role of MRI in diagnosis of this disease and description of surgical types of arterial and venous root compression. Authors demonstrated that high effectiveness of vascular decompression depends on correct clinical diagnosis.

[Role of polyclinic rehabilitation level in correcting psychoemotional state in workers with high occupational risk].

The authors evaluated health resources and psychologic state of locomotive engine operators with arterial hypertension. Analysis covered emotional stability, anxiety, general self-appraisal; polyclinic rehabilitation program appeared to have positive psycho-correcting effect.